Protein corona hampers targeting potential of MUC1 aptamer functionalized SN-38 core-shell nanoparticles.

Nanoparticles have been considered to improve delivery and physicochemical characteristics of bioactive agents in recent years. In this study, a core-shell chitosan nanoparticulate system was prepared for the targeted delivery of SN-38. SN-38, an active metabolite of camptothecin, conjugated to hyaluronic acid (HA) was used as the shell of chitosan nanoparticles decorated with MUC1 aptamer. The conjugation was confirmed by UV and (1)H NMR techniques. Targeting efficiency was evaluated by confocal microscopy and flow cytometry. It was shown that MUC1 decoration increased the uptake of nanoparticles by HT29 cells, MUC1 positive cell line, while CHO as MUC1 negative cell line showed no enhanced uptake of decorated nanoparticles. Compared to non-targeted nanoparticles, flow cytometric annexin V/PI analyses showed that the nanoparticles exert cytotoxicity through apoptosis. It was, however, shown that protein corona adsorption at the surface of nanoparticles hampered the cytotoxicity of nanoparticles, as there was no difference between the cytotoxicity of targeted and non-targeted nanoparticles, when treated with bovine serum albumin prior to cytotoxicity study.

[1]  S. Ostad,et al.  Human Serum Albumin Conjugates of 7-Ethyl-10-hydroxycamptothecin (SN38) for Cancer Treatment , 2014, BioMed research international.

[2]  H. Zhao,et al.  20-O-acylcamptothecin derivatives: evidence for lactone stabilization. , 2000, The Journal of organic chemistry.

[3]  Joel L. Bargul,et al.  Erratum to “Use of Metarhizium anisopliae Chitinase Genes for Genotyping and Virulence Characterization” , 2014, BioMed Research International.

[4]  S. Thang,et al.  RAFT‐Derived Polymer–Drug Conjugates: Poly(hydroxypropyl methacrylamide) (HPMA)–7‐Ethyl‐10‐hydroxycamptothecin (SN‐38) Conjugates , 2012, ChemMedChem.

[5]  M. Ramesh,et al.  Irinotecan and its active metabolite, SN-38: review of bioanalytical methods and recent update from clinical pharmacology perspectives. , 2010, Biomedical chromatography : BMC.

[6]  Felix Hueber,et al.  Applied Therapeutics The Clinical Use Of Drugs , 2016 .

[7]  H. Kuga,et al.  Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. , 1991, Cancer research.

[8]  A. Ray,et al.  Carboxyl-terminated PAMAM-SN38 conjugates: synthesis, characterization, and in vitro evaluation. , 2010, Bioconjugate chemistry.

[9]  Iseult Lynch,et al.  What the cell "sees" in bionanoscience. , 2010, Journal of the American Chemical Society.

[10]  Weihong Tan,et al.  Aptamer-conjugated nanoparticles for selective collection and detection of cancer cells. , 2006, Analytical chemistry.

[11]  Lisa Brannon-Peppas,et al.  Active targeting schemes for nanoparticle systems in cancer therapeutics. , 2008, Advanced drug delivery reviews.

[12]  M. Cowman,et al.  Experimental approaches to hyaluronan structure. , 2005, Carbohydrate research.

[13]  F M van den Berg,et al.  Expression of CD44 variant proteins in human colorectal cancer is related to tumor progression. , 1993, Cancer research.

[14]  H. Kuh,et al.  Injectable poly(organophosphazene)-camptothecin conjugate hydrogels: synthesis, characterization, and antitumor activities. , 2012, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[15]  N. M. Zaki,et al.  Chitosan/TPP and Chitosan/TPP-hyaluronic Acid Nanoparticles: Systematic Optimisation of the Preparative Process and Preliminary Biological Evaluation , 2009, Pharmaceutical Research.

[16]  R. J. Lee,et al.  Targeted drug delivery via the folate receptor. , 2000, Advanced drug delivery reviews.

[17]  J. Benoit,et al.  5-ASA loaded chitosan-Ca-alginate microparticles: Preparation and physicochemical characterization. , 2007, International journal of pharmaceutics.

[18]  Robert Langer,et al.  Nanotechnology and Aptamers: Applications in Drug Delivery , 2022 .

[19]  J. Richie,et al.  Targeted nanoparticle-aptamer bioconjugates for cancer chemotherapy in vivo. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[20]  A. Spicer,et al.  Hyaluronan: a multifunctional, megaDalton, stealth molecule. , 2000, Current opinion in cell biology.

[21]  Robert Langer,et al.  Nanoparticle–aptamer bioconjugates for cancer targeting , 2006, Expert opinion on drug delivery.

[22]  Marco P Monopoli,et al.  Biomolecular coronas provide the biological identity of nanosized materials. , 2012, Nature nanotechnology.

[23]  A. Barbas,et al.  The development and testing of aptamers for cancer. , 2009, Current opinion in investigational drugs.

[24]  Raimo Hartmann,et al.  Temperature: the "ignored" factor at the NanoBio interface. , 2013, ACS nano.

[25]  M. Alonso,et al.  Novel hydrophilic chitosan‐polyethylene oxide nanoparticles as protein carriers , 1997 .

[26]  M. Mahmoudi,et al.  Protein-nanoparticle interactions: opportunities and challenges. , 2011, Chemical reviews.

[27]  Robert Langer,et al.  Targeted delivery of cisplatin to prostate cancer cells by aptamer functionalized Pt(IV) prodrug-PLGA–PEG nanoparticles , 2008, Proceedings of the National Academy of Sciences.

[28]  Jian Huang,et al.  Novel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studies. , 2013, Journal of controlled release : official journal of the Controlled Release Society.

[29]  Chunsheng Kang.  Gene Therapy - Developments and Future Perspectives , 2011 .

[30]  F. Atyabi,et al.  MUC1 aptamer conjugated to chitosan nanoparticles, an efficient targeted carrier designed for anticancer SN38 delivery. , 2014, International journal of pharmaceutics.

[31]  A. Serafino,et al.  CD44-targeting for antitumor drug delivery: a new SN-38-hyaluronan bioconjugate for locoregional treatment of peritoneal carcinomatosis. , 2011, Current cancer drug targets.

[32]  I. Ojima,et al.  Recent Advances in Tumor-Targeting Anticancer Drug Conjugates , 2005 .

[33]  J. Gariépy,et al.  Phototoxic aptamers selectively enter and kill epithelial cancer cells , 2008, Nucleic acids research.

[34]  F. Gu,et al.  Formulation/preparation of functionalized nanoparticles for in vivo targeted drug delivery. , 2009, Methods in molecular biology.

[35]  M. Thanou,et al.  Targeting nanoparticles to cancer. , 2010, Pharmacological research.

[36]  F. Marcucci,et al.  Active targeting with particulate drug carriers in tumor therapy: fundamentals and recent progress. , 2004, Drug discovery today.

[37]  Makobetsa Khati,et al.  The future of aptamers in medicine , 2010, Journal of Clinical Pathology.

[38]  Robin P Boushey,et al.  Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. , 2009, Clinics in colon and rectal surgery.

[39]  Mary Anne Koda-Kimble,et al.  Applied Therapeutics: The Clinical Use of Drugs , 1992 .

[40]  Jianjun Cheng,et al.  Protein corona significantly reduces active targeting yield. , 2013, Chemical communications.

[41]  Jianjun Cheng,et al.  Synthesis of linear, beta-cyclodextrin-based polymers and their camptothecin conjugates. , 2003, Bioconjugate chemistry.

[42]  E. Azizi,et al.  Preparation and in vitro evaluation of actively targetable nanoparticles for SN-38 delivery against HT-29 cell lines. , 2010, Nanomedicine : nanotechnology, biology, and medicine.

[43]  Sanjay K. Jain,et al.  In vitro and cell uptake studies for targeting of ligand anchored nanoparticles for colon tumors. , 2008, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[44]  Hong Zhao,et al.  Novel prodrugs of SN38 using multiarm poly(ethylene glycol) linkers. , 2008, Bioconjugate chemistry.